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ORIGINAL ARTICLE 
Pharmacodynamic properties of HMR 3004, a novel 
ketolide, on respiratory pathogens, enterococci and 
Bacteroides frugilis demonstrated by studies of time kill 
kinetics and postantibiotic effect 
E l .  Boswell, J. 111. Andrews and R. Wise 
Department of Medical Microbiology, City Hospital NHS Trust, Dudley Road ,  Birmingham, UK 
Objective: The pharmacodynamic properties of the novel ketolide (a new class of macrolide) antibiotic, HMR 3004, 
were investigated by studying time-kill kinetics and postantibiotic effect. 
Methods: The time-kill kinetics were studied at two inocula against three strains each of Staphylococcus aureus, 
Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneurnoniae, Streptococcus pyogenes, Enterococcus 
faecalis, Enterococcus faecium and Bacteroides fragilis. The postantibiotic effects of HMR 3004 were also investigated 
on these organisms at concentrations equivalent to 1, 4 and 10 x MIC. 
Results: The time kill-kinetic data demonstrated that HMR 3004 is inoculum dependent and predominantly 
bacteriostatic being only slowly bactericidal at higher concentrations. HMR 3004 exhibited a significant postantibiotic 
effect with all strains studied, ranging from 1.9-6.2 h at 10 x MIC. 
Conclusions: The bacteriostatic activity and significant postantibiotic effect demonstrated by HMR 3004 are similar t o  
those previously obtained with other macrolides. 
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INTRODUCTION 
The ketolide H M R  3004 belongs to a new 14- 
membered ring macrolide class of antibiotics which are 
characterized by a 3-keto group on the erythronolide 
A ring instead of the a-L-cladinose moiety [l]. The 
ketolides possess the antibacterial spectrum of erythro- 
mycin A [2], and H M R  3004 has demonstrated out- 
standing activity against multiresistant pneumococci 
and activity against Haemophilus irguenzae, Stuepto- 
coccus yneumoniae and the enterococci. Against strains 
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susceptible to macrolides, the activity of H M R  3004 is 
one to two orders of magnitude higher than that of 
clarithromycin and erythromycin [3]. 
Pharmacodynamic parameters have become in- 
creasingly important for the determination of optimal 
dosing schedules of antibiotics. The in vitro pharma- 
codynamic parameters of an antimicrobial include time 
kill kinetics and postantibiotic effect (PAE). Time kill 
curves are pharmacodynamic examples of bactericidal 
activity expressed as rate of killing by a fixed concen- 
tration of antimicrobial and constitute one of the most 
reliable methods of determining tolerance 141. PAE is 
the term used to describe the continued suppression of 
the growth of an organism after a short exposure to an 
antimicrobial agent [5]. Clinically, the importance of 
PAE is in antimicrobial agent dosing regimens and it is 
particularly relevant to short half-life compounds. An 
infection caused by an organism susceptible to an agent 
with a significant PAFi may require less fiequent dosing 
than an infection susceptible to agents that do not 
demonstrate a PAE, other factors being equal. 
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We investigated the rate of killing and PAE of 
HMR 3004 on aerobic bacteria implicated in upper 
and lower respiratory tract infections, and, in addition, 
enterococci and the anaerobe Bucteroides jugilis. The 
effect of two inocula on the rate of kill was studied. 
Previous pharmacodynamic studies have shown that 
erythromycin A is predominantly bacteriostatic, although 
at hgher concentrations it is slowly bactericidal [6]. 
Macrolides have demonstrated significant PAEs of 
> 3 h with staphylococci and streptococci [5]. 
MATERIALS AND METHODS 
Bacterial strains and culture conditions 
Two recent clinical isolates and a type culture of each 
of the following organisms were studied: Staphylococcus 
uureus and ATCC 29213, H .  influenzue and NCTC 
10479, Moruxellu cuturrhalis and NCTC 3622, Strepto- 
coccus pneumoniue and NCTC 7465, Enterococcus faecalis 
and NCTC 12201, E.  fuecium and NCTC 12204 and 
B. jugilis and NCTC 9343. Three recent clinical 
isolates of Streptococcus pyogenes were also included. Iso- 
Sensitest agar and broth (Unipath, Basingstoke, UK) 
supplemented with 20 mg/L nicotinamide adenine 
dinucleotide (NAD) (Sigma, Poole, UK) and 5% horse 
blood (E and 0 Laboratories Ltd, Bonnybridge, UK) 
were used for the aerobic bacteria. Wilkins-Chalgren 
agar and broth (Unipath) were used throughout for 
the anaerobic investigations. AU the anaerobic work was 
performed in an anaerobic cabinet (Don Whitley 
Scientific Ltd, Skipton, UK) containing an atmosphere 
of 80% nitrogen, 10% carbon dioxide and 10% 
hydrogen. To ensure anaerobiosis, broths and diluents 
were incubated in the cabinet for at least 48 h before 
use and a reasazurin indicator (BDH, Poole, UK) was 
employed. 
Antimicrobial agent 
HMR 3004 was obtained &om Roussel UCLAF, Paris, 
France. It was stored and prepared throughout these 
studies using the manufacturer's guidelines. 
MIC determinations 
MICs were determined for all organisms studied by 
a broth dilution method 171 with an inoculum of 
approximately 5 x lo5 CFU/mC. The MIC was defined 
as the lowest concentration at which there was no 
visible growth after 18-24 h (48 h for anaerobes) of 
incubation at 35-37 "C. 
Time kill kinetics 
HMR 3004 stock solutions were added to logarithmic- 
phase broth cultures of approximately lo5 and lo7 
CFU/mL, to give concentrations equivalent to 2 and 
10xMIC. An antibiotic-f?ee growth control was in- 
cluded at both inocula. Viable counts were performed 
(three replicates) at 0, 2, 4, 6 and 24 h after antibiotic 
addition, by the Miles and Misra technique [8], on agar 
plates following serial dilution in phosphate-buffered 
sahne, pH 7.3 (Unipath). The bacteria were enumerated 
after 48 h of incubation at 35-37°C and the time kill 
kinetics were plotted as loglo CFlJ/mC against time. 
Bactericidal activity is defined as a 3 loglo decrease in 
CFU/mL (99.9% kill) [4]. The lower limit of bacterial 
enumeration using this method was 2.7 loglo CFU/mL. 
Bacteriostatic activity was defined a: a < 2 loglo decrease 
in CFU/mL. Antibiotic carryover was not deemed 
to be a problem in our determinations as this occurs 
at higher concentrations of >16xMIC [4] and serial 
dilution was employed, whch minimizes any carryover 
effects. 
Postantibiotic effect 
HMR 3004 stock solutions were added to logarithmic- 
phase broth cultures of approximately lo5 CFU/mC, to 
give concentrations equivalent to 1 ,  4 and 10 x MIC, 
and a ketolide-free culture was included as a growth 
control. The cultures were incubated at 35-37°C for 
1 h. The HMR 3004 concentration:; were then reduced 
by 1000-fold dilution into prewarined broth and the 
cultures were incubated at 35-37°C for 24 h. The 
control cultures were treated in exxtly the same way. 
Viable counts were performed on antibiotic-bee agar 
plates prior to exposure, hourly fcbr 6 h and at 24 h 
after neutralization by dilution. Viable counts were 
determined with a spiral plater @on Whitley Scientific 
Ltd) following appropriate dilution in phosphate- 
buffered saline, pH 7.3. The bacteria were enumerated 
after 24 h of incubation at 35-37°C. The counts of 
loglo CFU/mL were plotted against time, and the PAE 
was defined as PAE = T - C, where T is the time 
required for the count in the test culture to increase 
1 loglo above the count observed immediately after 
dilution, and C is the time required for the count in 
the control to increase 1 loglo above the count observed 
immediately after ddution [5]. A significant PAE is 
defined as >0.5 h. 
RESULTS 
MlCs 
Table 1 shows that HMR 3004 has activity against 
respiratory pathogens, enterococci and B. jugilis. 
l ime kill kinetics 
Figure 1 depicts the time kill curves of HMR 3004 
against Staphylococcus aureus ATCC 29213, E .  faecalis 
T398 and B. jugilis B1 studied at an inoculum of 
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Table 1 Bactericidal rates (change in loglo CFU/mL) of HMR 3004 at concentrations equivalent to 2 and 10 X MIC 
Change in logto CFU/mL from 0 to 24 h 
MIC lo7 CFU/mL lo7 CFU/mL lo5 CFU/mL 10’ CFU/mL 
Strain (mg/L) 2 x MIC 10 x MIC 2 X MIC 10 x MIC 
Stuphylocorms uunus ATCC 2921 3 0.03 2.33 0.93 0.65 2-3.28 
Staphylococcus aureus F551 0.03 2.15 2.42 3.98 1.30 
Staphylococcus aureus F104 0.03 2.22 -1.19 1.25 >-3.11 
Streptococcus pnenmoniae NCTC 7465 0.008 ND ND ND ND 
Streptococcus pneumoniae P59 1 0.008 ND ND ND ND 
H. infuenzae NCTC 10479 1 1.61 -3.03 1.16 -3.2.5 
Streptococcus pneurnoniae P416 0.008 ND ND ND ND 
H. injuewzar A40 0.5 1.59 0.93 0.32 -3.23 
H. injutenzae A330 1 1.52 1.18 -0.03 -3.28 
M .  cutarrhalis NCTC 3622 0.06 -1.14 -1.23 >-2.28 >-3.18 
M .  cutarrhalis R79 0.06 -1.18 -1.21 -2.08 2-1.84 
M. catarrhalis R65 0.06 -1.04 -1.41 >-3.15 >-3.18 
Streptoconuc pyogenes P44 0.008 0.80 1.05 3.53 >-3.18 
Streptococcus pyqenes P199 0.008 1.27 -0.37 2.00 >-2.15 
Streprococcus pyopnes P404 0.008 -0.70 -1.70 1.65 >-2.48 
E. faecalis NCTC 12201 1 I .60 1.38 3.49 2.22 
E. faecalis T392 0.03 1.84 1.58 3.30 1.98 
E.  faecium NCTC 12204 0.5 2.01 1.67 3.48 -1.10 
E. faebum T445 0.015 1.64 1.65 3.39 0.10 
E. Jieculis T398 0.03 1.60 1.39 3.30 2.08 
E. fhecium T388 0.015 1.66 1.43 3.66 3.62 
B. jagilis NCTC 9343 1 >-5.20 >-5.20 >-3.28 >-3.28 
B. -fiufilis Bl 0.25 >-5.36 >-5.08 >-3.11 >-3.08 
B. frugilis B2 1 -1.95 >-5.18 >-3.15 -3.00 
ND, not determinable due to autolysis. 
approximately lo5  CFU/mL. Table 1 summarizes the 
bactericidal rates (change in loglo CFU/mL from 0 to 
24 h) of HMR 3004 on all strains investigated in this 
study. Bactericidal activity is defined as a 3 loglo 
decrease in CFU/mL; however, in some instances when 
studying the 10’ CFU/mL inoculum a 3 loglo decrease 
could not be determined (due to lower limit of 
detection) but a decrease of > 2  loglo was observed. In 
these cases, if no regrowth was observed for the 
duration of the experiment, the effect was termed 
bactericidal. The time kill kinetic data demonstrated 
that HMR 3004 is predominantly bacteriostatic and 
only slowly bactericidal at  higher concentrations. The 
10 x MIC concentration of HMR 3004 was bactericidal 
(99.9% lull) at 24 h with all strains except Staphylococcus 
aumus F55 1, the enterococci and Streptococcus pneu- 
moniae at inocula of lo5 CFU/mL. The 10 X MIC 
concentration of HMR 3004 was bactericidal at 4-6 h 
with the Streptococcus pneumoniae strains at inocula of 
lo5 CFU/mL, except for strain P416, on which HMR 
3004 was bacteriostatic. The 10 X MIC concentration 
of HMR 3004 was bactericidal at 24 h and at an 
inoculum of lo7 CFU/mI, only for one strain of H. 
infuenzae and B. fragilis strains. The 2 x MIC concen- 
tration of HMR 3004 was bactericidal at 24 h only 
with all strains of B. jiagilis and M. cafarrhalis at inocula 
of l o 5  CFU/mL. 
Postantibiotic effect 
Figure 2 depicts the PAE of HMR 3004 on Staphylo- 
coccus aureus ATCC 29213, E. faecalis T398 and B. 
jagilis B1. Table 2 summarizes the PAE (h) of HMR 
3004 for all the strains investigated in this study. HMR 
3004 exhibited a sipficant PAE with all strains studied 
at 4 and 10 x MIC. The PAEs at 1, 4 and 10 x MIC 
of HMR 3004 were 0-3.5, 1.1-5.5 and 1.9-6.2h, 
respectively. 
DISCUSSION 
Our MIC data confirm the preliminary study by 
Agouridas et al [3], in that the ketolides have activity 
against respiratory pathogens and enterococci. The 
time kill kinetic data demonstrate that HMR 3004 
exhibits concentration- and inoculum-dependent 
bacteriostatic activity on all strains studied. Slow time- 
dependent bactericidal activity (99.9% kill at 24 h) was 
only seen at the hgher concentration stuhed, but not 
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Figure 1 HMR 3004 time kill curves of (a) Staphylococcus aureus ATCC 29213, (b) E. faecalis T398, (c) B. 3ugilis B1, (d) 
MIC. 
Sfreptococms pneumoniae P591, (e) Streptoroms pyogenes P199, and (0 M.  raturrhalis R65. -, control; .. 2 >< MIC; .... 10 X 
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Figure 2 HMR 3004 postantibiotic effect on (a) 
Staphylococms aurew ATCC 29213, (b) E. faecalis T398, 
(c) B.jugilis B1. -, control; .. 1 x MIC; .... 4 X MIC; 
-, 10 X MIC. 
Table 2 HMR 3004 postantibiotic effect (h) 
Strain 
HMR 3004 
1 x M I C  4 x M I C  IOxMIC: 
Staphylococcus aurecis 
ATCC 29213 
Staphylococcus aureus F55 1 
Staphylococcus aureus F104 
Streptococcus pneumoniae 
Streptococcirs pneumoniae P j 9  1 
Streptococcus pneirmoniae P4 16 
H. in jumzae N C T C  10479 
H. injuenzae A40 
H .  i~Juenzne  A330 
M. catarrhalis N C T C  3622 
M. cararrhalis R79 
M. catarrhalis R65 
Streptococcus pyofenes P44 
Streptococcus p y o p r s  P139 
Streptomrrus pyopnes P404 
E. fiecalis NCTC 12201 
E. faecalis T392 
E. faecalis T398 
E. faecium NCTC 12204 
E. faecium T388 
E. faerium T445 
B..fragilis N C T C  9343 
B. jkgilis H 1 
B. fragilis B2 
NCTC 7465 
0.8 
0.8 
0.3 
0.8 
1.0 
0.4 
0.0 
0.3 
0.6 
1 .0 
0.0 
0.5 
0.0 
0.2 
1.2 
3.5 
1.3 
0.5 
3.1 
1.2 
1.2 
2.9 
2.5 
1.8 
5.5 5.5 
2.7 3.4 
3.1 4.3 
3.1 6.2 
3.7 6.2 
1.2 3.7 
1.6 2.3 
2.2 2.5 
1.1 3.3 
2.0 3.6 
3.0 3.1 
3.5 5.0 
1.6 6.1 
2.0 5.0 
3.5 4.8 
2.9 3.7 
2.8 3.1 
2.6 2.3 
2.5 3.7 
2.0 1 .? 
1.4 3.2 
2.6 3.4 
2.3 2.2 
2.2 2.3 
ND, not determinable 
with all strains. HMR 3004 exhibited the most rapid 
bactericidal activity on the Str~tococtl*spneumo~iue strains. 
The predominant bacteriostatic activity exhibited by 
HMR 3004 is similar to that observed with erythro- 
mycin A [6].  Regrowth was observed during this 
study, and the colonies observed were morphologically 
identical and had MICs the same as or within one 
dilution step of the controls. The clinical importance 
of regrowth is unclear, particularly if it occurs after the 
usual dosing interval [4]. 
Bacterial growth suppression termed PAE has been 
observed since the advent of antibiotic therapy The 
mechanism and relevance of PAE are still poorly 
understood, but clinically, its greater impact is on 
designing dosing regimens for new antimicrobials. 
There is inadequate clinical evidence to suggest 
an optimal dosage regimen for macrolides. The most 
common explanations for the mechanism of PAE 
are prolonged persistence of the antimicrobial at  the 
cellular site of action or the true recovery period fi-om 
non-lethal damage [5]. For macrolides, the duration of 
the PAE may be equivalent to the time required for the 
macrolide to detach &om the ribosome. HMR 3004 
produced a significant concentration-dependent PAE. 
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The increase in PAE with an increase in concentration 
was shown with all strains. For example, PAEs at 1, 4 
and 10 X MIC of 0.8, 2.7 and 3.4 were seen for HMR 
3004 on Staphylococcus aureus F551 strain. PAEs of other 
macrolides are similar to the PAE we observed for 
HMR 3004. Odenholt-Tornqvist et al [9] reported 
PAEs of 2.9-8 h for roxithromycin, clarithromycin and 
azithromycin with Streptococcus pyogenes, Streptococcus 
pneumoniae and H. infuenzae. Scaghone et al [lo] also 
reported a clarithromycin PAE of 2 4 h for Streptococcus 
pyogenes, Staphylococcus aureus and H. infuenzae. In 
addition, Munckhof and Turnidge [l 11 recently reported 
similar PAEs as demonstrated here with Staphylocom 
aureus, Streptococcus pyogenes and Streptococcus pneumoniae. 
The PAE of HMR 3004 exhibited considerable strain 
and interspecies variation; this variation has been noted 
with other antimicrobials [12]. 
In conclusion, it would appear that HMR 3004 
exhibits pharmacodynamic properties similar to those 
of erythromycin A, i.e. they are slowly bactericidal at 
high concentrations and exhibit a significant PAE. 
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